CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
复制标题
CHOP-21 用于治疗实体器官移植后的移植后淋巴增殖性疾病 (PTLD)。
作者：
S. Choquet;R. Trappe;V. Leblond;U. Jäger;F. Davi;S. Oertel
对于免疫抑制减少无效的移植后淋巴增生性疾病（PTLD），目前尚无明确的治疗方法。中位随访时间为8.8年，目前对26例PTLD成人患者进行的标准CHOP（环磷酰胺、多柔比星、长春新碱和泼尼松）的回顾性分析显示，总缓解率为65%，中位总生存期和无进展生存期分别为13.9个月和42个月。
There is no definitive treatment for post-transplant lymphoproliferative disorder (PTLD) that does not respond to reduction of immunosuppression. With a median follow-up of 8.8 years, the current retrospective analysis of standard CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) in 26 adults with PTLD demonstrated an overall response rate of 65% and median overall and progression-free survivals of 13.9 and 42 months, respectively.